TDP2 and cancer: These results corroborate the conclusion that TTRAP rely on IL-6 to dampen T cell-mediated antitumor immunity and foster tumor progression, and suggest that targeting TRAPs or IL-6 may be an effective therapeutic strategy for improving cancer immunotherapy.